Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC).
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.11569
Abstract: 11569Background: No validated prognostic biomarker is currently available for mCRC. This trial assessed cfDNA and MTV before treatment with regorafenib as prognostic biomarkers for progression-free... read more here.
Keywords: dna cfdna; baseline cell; free dna; cfdna metabolic ... See more keywords
Co-isolation and analysis of extracellular vesicle (EV)-associated DNA and cell free DNA (cfDNA) to improve the diagnostic and prognostic value of circulating BRAF V600E in metastatic melanoma patients.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21564
Abstract: e21564Background: Detection of BRAF V600E on cell free tumor DNA (cfDNA) is emerging as a promising means to improve patient’s stratification or enable BRAFi therapy monitoring in a minimally invas... read more here.
Keywords: braf v600e; dna cfdna; cell free; dna ... See more keywords
Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.579
Abstract: 579Background: Fibroblast growth factor receptor 2 (FGFR2) alterations occur in 11% of cholangiocarcinomas, 85% of which are fusions. A multicenter, open-label, phase II study is currently evaluati... read more here.
Keywords: phase; dna cfdna; circulating free; free dna ... See more keywords
Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.174
Abstract: 174Background: Docetaxel (D) and cabazitaxel (C) are standard chemotherapies for mCRPC. A reliable biomarker predictive of resistance to D or C is yet to be identified. We aimed to assess the assoc... read more here.
Keywords: dna cfdna; biomarker; circulating free; free dna ... See more keywords